MRNA · Moderna, Inc.

Healthcare NMS United States modernatx.com ↗
Val Gro Qua Mom Sta Cap P/S25.80 P/E Fwd P/E-32.22 PEGN/A 52W –  RSI Target$119.56 (-17.0%) Beta1.11 Div
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Biotechnology Cambridge, United States 4,700 employees
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 61 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
3Bearish
0Neutral

Key Signals 1

▲ Double Bottom Major reversal 2026-06-04 · $49.26
Two lows ~$44.76 — bullish reversal confirmed
Learn more →

Momentum Signals 6

▲ MACD Bullish Crossover 2026-05-08 · $54.35
▲ MACD Bullish Crossover 2026-06-03 · $49.06
▲ MACD Bullish Crossover 2026-08-10 · $59.81
▼ MACD Bearish Crossover 2026-05-19 · $45.72

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Nov 05, 2026
Beat Rate 88%
Consensus HOLD
Analyst Upside -17.0%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
88% 7/8 quarters
Wall Street Consensus
HOLD
5
16
2
BuyHoldSell
Price Target Range
$119.56 -17.0% upside
Low $45 High $170
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin -66.02%Last 12 Months
Operating Margin -557.93%Last 12 Months
Return on Equity -39.00%Last 12 Months
Revenue Growth 2.10%Year over Year
Free Cash Flow 299.25MLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 19.04Most Recent Quarter
Current Ratio 2.29Most Recent Quarter
Cash 5.14BMost Recent Quarter
Total Debt 1.29BMost Recent Quarter
Net Debt Most Recent Quarter
How MRNA Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap57.48B
Enterprise Value53.63B
Trailing P/EN/A
Forward P/E-32.22
PEG Ratio (5yr)N/A
Price/Sales (ttm)25.80
Price/Book (mrq)8.50
EV/Revenue24.07
EV/EBITDA-24.43
Share Statistics
Avg Vol (3m)16.11M
Shares Outstanding399.24M
Float372.26M
% Held by Insiders7.32%
% Held by Institutions80.45%
Short Ratio1.36
Short % of Float11.98%
Profitability
Gross Margin-66.02%
Operating Margin (ttm)-557.93%
Profit Margin-141.43%
Return on Assets (ttm)-13.26%
Return on Equity (ttm)-39.00%
Income Statement
Revenue (ttm)2.23B
Revenue Growth (yoy)2.10%
Gross Profit (ttm)-1.47B
EBITDA-2.20B
Net Income (ttm)-3.15B
Diluted EPS (ttm)-8.41
EPS Growth (yoy)N/A
Balance Sheet
Total Cash (mrq)5.14B
Total Debt (mrq)1.29B
Debt / Equity (mrq)19.04
Current Ratio (mrq)2.29
Book Value / Share16.95
Operating CF (ttm)-1.07B
Free Cash Flow (ttm)299.25M
Trading & Dividends
Beta (5Y)1.11
50-Day MA89.61
200-Day MA56.53
Fwd Dividend YieldN/A
Payout Ratio0.00%

No dividend history available for MRNA.

Ownership Breakdown
Institutional 80.45% Insider 7.32% Public 12.2%
Short Interest 11.98% of float
High
Institutional 13F Holdings

Famous investors who disclosed a position in MRNA in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value